Page 56 - Go4it

Chapter 4
Table 2: As Continued
Fasting glucose, mmol/l I
C Glucose 120 min, mmol/l I C Fasting insulin, pmol/l I C Insulin 30 min, pmol/l I C Insulin 120 min, pmol/l I C HOMA-IR I C Systolic blood pressure, mmHg I
25.2 (5.4) 24.1 (4.6) 5.0 (0.4) 5.0 (0.4) 5.9 (1.1) 6.0 (0.9) 125 (63) 133 (75) 1280 (610) 1177 (804) 661 (424) 671 (404) 4.7 (2.6) 5.0 (3.0)
113 (13) 25.2 (5.4)
112 (13) 24.1 (4.6)
63 (8) 5.0 (0.4)
62 (8) 5.0 (0.4)
1.15 (0.25) 5.9 (1.1)
1.19 (0.22) 6.0 (0.9)
5.0 (0.4) 5.1 (0.4) 5.9 (1.0) 6.0 (1.3) 127 (54) 132 (62) 1163 (611) 1379 (1119) 565 (366) 605 (493) 4.8 (2.3) 5.0 (2.4) 112 (14) 110 (12)
62 (8) 5.0 (0.4)
62 (7) 5.1 (0.4)
1.12 (0.22 5.9 (1.0)
1.13 (0.19) 6.0 (1.3)
1.08 (0.59) 127 (54)
1.00 (0.42) 132 (62)
5.3 (0.5) 5.0 (0.4) 5.9 (1.1) 6.1 (1.3) 118 (66) 122 (57) 1115 (858) 1387 (941) 611 (513) 660 (520) 5.7 (2.7) 4.6 (2.2) 114 (10) 115 (10)
64 (8) 5.3 (0.5)
63 (11) 5.0 (0.4)
1.13 (0.19) 5.9 (1.1)
1.10 (0.28) 6.1 (1.3)
0.99 (0.49) 118 (66)
1.06 (0.58) 122 (57)
-0.07 (-0.47; 0.32 -0.01 (-0.87; 0.88 -0.30 (-22; 21)
-265 (-586; 55)
-23 (-193; 148) -0.08 (-0.98; 0.82 1.54 (-2.80; 5.89)
-0.41 (-3.46; 2.63 -0.07 (-0.47; 0.32)
0.02 (-0.04; 0.08) -0.01 (-0.87; 0.88)
.06 (-0.09; 0.21) -0.30 (-22; 21)
Chapter 4
Table 2: As Continued
C
Diastolic blood pressure, mmHg I Fasting glucose, mmol/l I
C C
HDL, mmol/l I Glucose 120 min, mmol/l I
C C
Triglycerides, mmol/l I Fasting insulin, pmol/l I
C C
The interaction of intervention*time was not significant for any of the outcome measurements, implying that the estima
Insulin 30 min, pmol/l I
significantly by intervention. Number of observations varied at 6 months from 49-53 in the intervention group and Numbers of observations varied aCt 18 mo1n3t3h(s75fr)om 33-361i3n79th(e11in1t9e)rvention 1g3r8o7up(9a4n1d) 27-32 in the control gro
125 (63) 1163 (611) 1115 (858) -265 (-586; 55)
C=Control group, b Mean (sd), c β (95% CI) adjusted for age, sex and ethnicity; bold type indicates p <0.05, d Group c
Insulin 120 min, pmol/l I
according the intention-to-treat principle with all subjects analyzed in the group to which they were randomly assi
1280 (610) 565 (366) 611 (513) -23 (-193; 148)
analysis, was used to assess the effect of the intervention over time adjusted for age, sex and ethnicity. Therefore, it is C 1177 (804) 605 (493) 660 (520)
between group difference based on Table 2. This method includes all assessments, at baseline as well as at 6 and 18 mo
HOMA-IR I
56
Systolic blood pressure, mmHg I
C Diastolic blood pressure, mmHg I C HDL, mmol/l I C Triglycerides, mmol/l I C
661 (424) 671 (404) 4.7 (2.6) 5.0 (3.0) 113 (13) 112 (13) 63 (8) 62 (8) 1.15 (0.25) 1.19 (0.22)
4.8 (2.3) 5.0 (2.4) 112 (14) 110 (12) 62 (8) 62 (7) 1.12 (0.22 1.13 (0.19) 1.08 (0.59) 1.00 (0.42)
5.7 (2.7) 4.6 (2.2) 114 (10) 115 (10) 64 (8) 63 (11) 1.13 (0.19) 1.10 (0.28) 0.99 (0.49) 1.06 (0.58)
-0.08 (-0.98; 0.82) 1.54 (-2.80; 5.89) -0.41 (-3.46; 2.63) 0.02 (-0.04; 0.08) .06 (-0.09; 0.21)
C
The interaction of intervention*time was not significant for any of the outcome measurements, implying that the estima significantly by intervention. Number of observations varied at 6 months from 49-53 in the intervention group and Numbers of observations varied at 18 months from 33-36 in the intervention group and 27-32 in the control grou C=Control group, b Mean (sd), c β (95% CI) adjusted for age, sex and ethnicity; bold type indicates p <0.05, d Group c according the intention-to-treat principle with all subjects analyzed in the group to which they were randomly assig analysis, was used to assess the effect of the intervention over time adjusted for age, sex and ethnicity. Therefore, it is between group difference based on Table 2. This method includes all assessments, at baseline as well as at 6 and 18 mo
56
) )
)
)
u g n
t 4
o
n n
Chapter 4
Table 2: As Continued
Fasting glucose, mmol/l I
25.2 (5.4) 24.1 (4.6) 5.0 (0.4) 5.0 (0.4) 5.9 (1.1) 6.0 (0.9) 125 (63) 133 (75) 1280 (610) 1177 (804) 661 (424) 671 (404) 4.7 (2.6) 5.0 (3.0) 113 (13) 112 (13) 63 (8) 62 (8) 1.15 (0.25) 1.19 (0.22)
5.0 (0.4) 5.1 (0.4) 5.9 (1.0) 6.0 (1.3) 127 (54) 132 (62) 1163 (611) 1379 (1119) 565 (366) 605 (493) 4.8 (2.3) 5.0 (2.4) 112 (14) 110 (12)
5.3 (0.5) 5.0 (0.4) 5.9 (1.1) 6.1 (1.3) 118 (66) 122 (57) 1115 (858) 1387 (941) 611 (513) 660 (520) 5.7 (2.7) 4.6 (2.2) 114 (10) 115 (10) 64 (8)
-0.07 (-0.47; 0.32) -0.01 (-0.87; 0.88) -0.30 (-22; 21) -265 (-586; 55) -23 (-193; 148) -0.08 (-0.98; 0.82) 1.54 (-2.80; 5.89) -0.41 (-3.46; 2.63) 0.02 (-0.04; 0.08)
0.15 (-0.02; 0.33) -0.05 (-0.56; 0.46) 0.93 (-23; 25) -262 (-634; 109) -1 (-206; 203) -0.16 (-1.08; 0.76) -2.78 (-7.86; 2.31) 0.84 (-2.70; 4.37) 0.07 (-0.001; 0.14) -0.08 (-0.26; 0.09)
C Glucose 120 min, mmol/l I C Fasting insulin, pmol/l I C Insulin 30 min, pmol/l I C Insulin 120 min, pmol/l I C HOMA-IR I C Systolic blood pressure, mmHg I C Diastolic blood pressure, mmHg I C HDL, mmol/l I C Triglycerides, mmol/l I C
62 (8)
62 (7) 1.12 (0.22 1.13 (0.19) 1.08 (0.59) 1.00 (0.42)
63 (11) 1.13 (0.19) 1.10 (0.28) 0.99 (0.49) 1.06 (0.58)
.06 (-0.09; 0.21)
The interaction of intervention*time was not significant for any of the outcome measurements, implying that the estimated time effect did not differ significantly by intervention. Number of observations varied at 6 months from 49-53 in the intervention group and 40-44 in the control group. Numbers of observations varied at 18 months from 33-36 in the intervention group and 27-32 in the control group. a I=Intervention group, C=Control group, b Mean (sd), c β (95% CI) adjusted for age, sex and ethnicity; bold type indicates p <0.05, d Group comparisons were performed according the intention-to-treat principle with all subjects analyzed in the group to which they were randomly assigned. Linear, mixed models analysis, was used to assess the effect of the intervention over time adjusted for age, sex and ethnicity. Therefore, it is not possible to calculate the between group difference based on Table 2. This method includes all assessments, at baseline as well as at 6 and 18 months.
56